FXN and Friedreich ataxia: In this present study, we show that FXN restoration via the same CRISPR/Cas9 gene editing approach was able to reverse many of the pathological features associated with FXN deficiency in FRDA patient-derived microglia, including mitochondrial and lysosomal abnormalities, possibly leading to attenuation of their inflammatory profile, which prevented neuronal death in vitro.